Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 3/2015

01-07-2015 | Research

Pathway Crosstalk Analysis of Microarray Gene Expression Profile in Human Hepatocellular Carcinoma

Authors: Xiaodong Zhou, Ruiguo Zheng, Huifang Zhang, Tianlin He

Published in: Pathology & Oncology Research | Issue 3/2015

Login to get access

Abstract

Liver cancer is the third most common cause of cancer death in the world. Hepatocellular carcinoma (HCC) is the main pathological types in liver cancer, which amounts to 70–85 % of primary liver cancer in the world and 90 % in China. The aim of this study was to establish a PPI network and a pathway crosstalk network to isolate important dysfunctional pathways which play an important role in the pathogenesis of HCC. System biology approach was used in this research. A PPI network was firstly built and then a dysfunctional crosstalk network of HCC related pathways was constructed. Several important significant dysfunctional crosstalk pathways were identified. Basal transcription factors (hsa03022), Glycerophospholipid metabolism (hsa00564) and Metabolism of xenobiotics by cytochrome P450 (hsa00980) were significantly interact with Pathway in cancer (hsa05200). Besides, pathway Axon guidance (hsa04360) was also dysfunctional crosstalk with Pathway in cancer (hsa05200). The crosstalks among these pathways reveal some evidence that the pathways closely cooperated and play important tasks in HCC progression. Besides, the pathway hsa04360 dysfunctional crosstalk with the hsa05200 indicates there would be a same mechanism for HCC invasion and migration.
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: globocan 2000. Int J Cancer 94(2):153–156CrossRefPubMed
2.
Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45(4):529–538CrossRefPubMed
3.
Tang Z-Y, Ye S-L, Liu Y-K, Qin L-X, Sun H-C, Ye Q-H, Wang L, Zhou J, Qiu S-J, Li Y (2004) A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130(4):187–196CrossRefPubMed
4.
Berger JC, Vander Griend D, Stadler WM, Rinker-Schaeffer C (2004) Metastasis suppressor genes: signal transduction, cross-talk and the potential for modulating the behavior of metastatic cells. Anti-Cancer Drugs 15(6):559–568CrossRefPubMed
5.
Berasain C, Ujue Latasa M, Urtasun R, Goñi S, Elizalde M, Garcia-Irigoyen O, Azcona M, Prieto J, Ávila MA (2011) Epidermal growth factor receptor (EGFR) crosstalks in liver cancer. Cancer 3(2):2444–2461CrossRef
6.
Dai R, Chen R, Li H (2009) Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells. Int J Oncol 34(6):1749–1757PubMed
7.
Berasain C, Castillo J, Prieto J, Avila MA (2007) New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 27(2):174–185CrossRefPubMed
8.
Chen L, Wang R-S, Zhang X-S (2009) Biomolecular networks: methods and applications in systems biology, vol 10. Wiley
9.
Zhao X-M, Wang R-S, Chen L, Aihara K (2008) Uncovering signal transduction networks from high-throughput data by integer linear programming. Nucleic Acids Res 36(9):e48–e48CrossRefPubMedCentralPubMed
10.
11.
Wang T, Gu J, Yuan J, Tao R, Li Y, Li S (2013) Inferring pathway crosstalk networks using gene set co-expression signatures. Mol BioSyst
12.
Stefanska B, Huang J, Bhattacharyya B, Suderman M, Hallett M, Han Z-G, Szyf M (2011) Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res 71(17):5891–5903CrossRefPubMed
13.
R TRDC (2008) A language and environment for statistical computing. R foundation for statistical computing
14.
Irizarry RA, Hobbs B, Collin F, Beazer‐Barclay YD, Antonellis KJ, Scherf U, Speed TP (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4(2):249–264CrossRefPubMed
15.
Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3(1):3
16.
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological):289–300
17.
Kanehisa M The KEGG database. In: Novartis Found Symp, 2002. pp 91–101
18.
Zanzoni A, Montecchi-Palazzi L, Quondam M, Ausiello G, Helmer-Citterich M, Cesareni G (2002) MINT: a Molecular INTeraction database. FEBS Lett 513(1):135–140CrossRefPubMed
19.
Mishra GR, Suresh M, Kumaran K, Kannabiran N, Suresh S, Bala P, Shivakumar K, Anuradha N, Reddy R, Raghavan TM (2006) Human protein reference database—2006 update. Nucleic Acids Res 34(suppl 1):D411–D414CrossRefPubMedCentralPubMed
20.
Stark C, Breitkreutz B-J, Chatr-Aryamontri A, Boucher L, Oughtred R, Livstone MS, Nixon J, Van Auken K, Wang X, Shi X (2011) The BioGRID interaction database: 2011 update. Nucleic Acids Res 39(suppl 1):D698–D704CrossRefPubMedCentralPubMed
21.
Birnbaum A (1954) Combining independent tests of significance*. J Am Stat Assoc 49(267):559–574
22.
Liu Z-P, Wang Y, Zhang X-S, Chen L (2010) Identifying dysfunctional crosstalk of pathways in various regions of Alzheimer’s disease brains. BMC Syst Biol 4(Suppl 2):S11CrossRefPubMedCentralPubMed
23.
Panani AD, Roussos C (2006) Cytogenetic and molecular aspects of lung cancer. Cancer Lett 239(1):1–9CrossRefPubMed
24.
Breuer R, Postmus P, Smit E (2005) Molecular pathology of non-small-cell lung cancer. Respiration 72(3):313–330CrossRefPubMed
25.
26.
Giatromanolaki A, Koukourakis M, O’Byrne K, Kaklamanis L, Dicoglou C, Trichia E, Whitehouse R, Harris A, Gatter K (1996) Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res 16(6B):3819PubMed
27.
Dobbelstein M, Wienzek S, Koenig C, Roth J (1999) Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 18(12):2101CrossRefPubMed
28.
Ortega S, Malumbres M, Barbacid M (2002) Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta (BBA)-Rev Cancer 1602(1):73–87CrossRef
29.
Roy B, Taneja R, Chambon P (1995) Synergistic activation of retinoic acid (RA)-responsive genes and induction of embryonal carcinoma cell differentiation by an RA receptor alpha (RAR alpha)-, RAR beta-, or RAR gamma-selective ligand in combination with a retinoid X receptor-specific ligand. Mol Cell Biol 15(12):6481–6487PubMedCentralPubMed
30.
Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA (2001) Methylation associated inactivation of RASSF1A from region 3p21. 3 in lung, breast and ovarian tumours. Oncogene 20(12):1509CrossRefPubMed
31.
Darnell JE (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2(10):740–749CrossRefPubMed
32.
Safe S, Abdelrahim M (2005) Sp transcription factor family and its role in cancer. Eur J Cancer 41(16):2438–2448CrossRefPubMed
33.
34.
Scott KE, Wheeler FB, Davis AL, Thomas MJ, Ntambi JM, Seals DF, Kridel SJ (2012) Metabolic regulation of invadopodia and invasion by acetyl-CoA carboxylase 1 and de novo lipogenesis. PLoS One 7(1):e29761CrossRefPubMedCentralPubMed
35.
Pyragius CE, Fuller M, Ricciardelli C, Oehler MK (2013) Aberrant lipid metabolism: an emerging diagnostic and therapeutic target in ovarian cancer. Int J Mol Sci 14(4):7742–7756CrossRefPubMedCentralPubMed
36.
Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7(10):763–777CrossRefPubMed
37.
Rodriguez-Antona C, Ingelman-Sundberg M (2006) Cytochrome P450 pharmacogenetics and cancer. Oncogene 25(11):1679–1691CrossRefPubMed
38.
39.
Bailey LR, Roodi N, Dupont WD, Parl FF (1998) Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 58(22):5038–5041PubMed
40.
Ishibe N, Hankinson SE, Colditz GA, Spiegelman D, Willett WC, Speizer FE, Kelsey KT, Hunter DJ (1998) Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses’ Health Study. Cancer Res 58(4):667–671PubMed
41.
Sadanandam A, Varney ML, Singh S, Ashour AE, Moniaux N, Deb S, Lele SM, Batra SK, Singh RK (2010) High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis. Int J Cancer 127(6):1373–1383CrossRefPubMedCentralPubMed
42.
Pan G, Zhang X, Ren J, Lu J, Li W, Fu H, Zhang S, Li J (2013) Semaphorin 5A, an axon guidance molecule, enhances the invasion and metastasis of human gastric cancer through activation of MMP9. Pathol Oncol Res 19(1):11–18. doi:10.​1007/​s12253-012-9550-8 CrossRefPubMed
43.
Pan G, Zhu Z, Huang J, Yang C, Yang Y, Wang Y, Tuo X, Su G, Zhang X, Yang Z (2013) Semaphorin 5A Promotes Gastric Cancer Invasion/Metastasis via Urokinase-Type Plasminogen Activator/Phosphoinositide 3-Kinase/Protein Kinase B. Digestive diseases and sciences: 1–8
Metadata
Title
Pathway Crosstalk Analysis of Microarray Gene Expression Profile in Human Hepatocellular Carcinoma
Authors
Xiaodong Zhou
Ruiguo Zheng
Huifang Zhang
Tianlin He
Publication date
01-07-2015
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2015
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-014-9855-x

Other articles of this Issue 3/2015

Pathology & Oncology Research 3/2015 Go to the issue

Research

Correlations Between Prognosis and Regional Biomarker Profiles in Head and Neck Squamous Cell Carcinomas

Research

Frameshift Mutations of MUC15 Gene in Gastric and its Regional Heterogeneity in Gastric and Colorectal Cancers

Research

JAK2 V617F, MPL, and CALR Mutations in Essential Thrombocythaemia and Major Thrombotic Complications: A Single-Institute Retrospective Analysis

Research

Association of Romo1 Gene Genetic Polymorphisms with Risk of Gastric Cancer in Northwestern Chinese Population

Communication

Prognostıc Value of Increased her2 Expression in Cancers of Pancreas and Biliary Tree

Research

Anaplastic Thyroid Cancer: Outcome and the Mutation/Expression Profiles of Potential Targets
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits